Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

Assessing the Clinical Utility of Proviral DNA-based Antiretroviral Drug Resistance Testing in Individuals Living with Human Immunodeficiency Virus Type 1

EF 2020-21

Résumé
Globally, Human Immunodeficiency Virus (HIV) infects 38 million people, including over 68,000 Canadians. These individuals must take antiretroviral therapy (ART) that blocks HIV replication and thereby significantly improves quality and duration of life. However, ART can be compromised by the emergence of HIV drug resistance (HIVDR). HIV evolves rapidly in a host because its reverse transcriptase enzyme makes errors during replication. If ART is not taken regularly, HIV may continue to replicate and these errors can introduce mutations that make HIV resistant to antiretrovirals. Current treatment guidelines recommend performing HIVDR testing before initiating ART so physicians can choose an appropriate ART regimen. HIVDR testing can only be performed on RNA from a patient's blood that contains high levels of HIV. This presents challenges when making treatment decisions for treating patients with undetectable HIV levels, especially those with incomplete or unknown treatment history, as traditional HIVDR testing cannot be performed. However, HIV integrates into a host's genome as proviral DNA and the prior circulating HIV variants in a host are archived in the proviral DNA. Hence, proviral DNA could be used to test for HIVDR, but it is not fully understood if DNA-based drug resistance testing is as reliable as current RNA-based methods. Thus, this project will use two studies to assess the concordance of HIVDR testing performed on HIV DNA and RNA samples in persons on ART with undetectable viral load. The first study will examine rates of concordance at the population level. The second will examine HIVDR in proviral DNA in a small cohort of participants using next-generation sequencing to investigate the persistence of drug resistance mutations in proviral DNA over time.
Programme
Master's Award: Canada Graduate Scholarships
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
449333
Name
Sudderuddin K Hanwei
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Assessing the Clinical Utility of Proviral DNA-based Antiretroviral Drug Resistance Testing in Individuals Living with Human Immunodeficiency Virus Type 1
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Antiretroviral Therapy; Archived Proviral Hiv Dna Genotype; Bioinformatics; Biostatistics; Hiv Antiretroviral Treatment Guidelines; Hiv Drug Resistance; Hiv-1; Hiv-1 Proviral Dna; Hiv-1 Proviral Dna Resistance Testing; Next-Generation Sequencing
Abstract
Globally, Human Immunodeficiency Virus (HIV) infects 38 million people, including over 68,000 Canadians. These individuals must take antiretroviral therapy (ART) that blocks HIV replication and thereby significantly improves quality and duration of life. However, ART can be compromised by the emergence of HIV drug resistance (HIVDR). HIV evolves rapidly in a host because its reverse transcriptase enzyme makes errors during replication. If ART is not taken regularly, HIV may continue to replicate and these errors can introduce mutations that make HIV resistant to antiretrovirals. Current treatment guidelines recommend performing HIVDR testing before initiating ART so physicians can choose an appropriate ART regimen. HIVDR testing can only be performed on RNA from a patient's blood that contains high levels of HIV. This presents challenges when making treatment decisions for treating patients with undetectable HIV levels, especially those with incomplete or unknown treatment history, as traditional HIVDR testing cannot be performed. However, HIV integrates into a host's genome as proviral DNA and the prior circulating HIV variants in a host are archived in the proviral DNA. Hence, proviral DNA could be used to test for HIVDR, but it is not fully understood if DNA-based drug resistance testing is as reliable as current RNA-based methods. Thus, this project will use two studies to assess the concordance of HIVDR testing performed on HIV DNA and RNA samples in persons on ART with undetectable viral load. The first study will examine rates of concordance at the population level. The second will examine HIVDR in proviral DNA in a small cohort of participants using next-generation sequencing to investigate the persistence of drug resistance mutations in proviral DNA over time.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Sudderuddin, K Hanwei
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~